[Photo by Yonhap]
SK bioscience has started a process for emergency use listing (EUL) of its Covid-19 vaccine SKYCovione with the World Health Organization (WHO), the company said on Thursday.
SKYCovione is South Korea’s first homegrown vaccine, which was approved by the Ministry of Food and Drug Safety in June.
The EUL system allows the WHO to evaluate unlicensed vaccines and therapeutics and make them available for emergency use in a health crisis such as Covid-19.
The listing is essential for vaccine providers to participate in bids by international health agencies, including UNICEF and Global Alliance for Vaccines and Immunization.
If the listing is completed within this year, SK bioscience will also be able to supply SKYCovione to the global market through the COVAX Facility.
SKYCovione already submitted a separate request for conditional approval of SKYCovione with the European Medicines Agency in July.
SK bioscience shares added 1.94 percent to 105,000 won in mid-day trade on Thursday.
[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]